Roth Capital Initiates Coverage Of Cyclacel By: MarketMinute.com Stock News February 04, 2010 at 16:17 PM EST Roth Capital initiated coverage of Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) with a Buy rating sending the stock price soaring 32 cents to close at $2.30.